OJGen  Vol.3 No.2 A , June 2013
Vectors for gene therapy: A place for DNA transposon
Author(s) Benoît Chénais*
ABSTRACT

Gene therapy offers important perspectives in current and future medicine but suffers from imperfect vectors for the delivery of the therapeutic gene. Most preclinical and clinical trials have been based on the use of viral vectors, which have evident advantages but also some serious disadvantages. In the past decade the use of DNA transposon-based systems for gene delivery has emerged as a non-viral alternative. DNA transposon vector engineering remains largely in a preclinical phase but some interesting results have been obtained. This mini-review aims to provide the current state of the art on DNA transposon vectors used in a gene therapy perspective.


Cite this paper
Chénais, B. (2013) Vectors for gene therapy: A place for DNA transposon. Open Journal of Genetics, 3, 1-11. doi: 10.4236/ojgen.2013.32A1001.
References
[1]   [1] Edelstein, M.L., Abedi, M.R. and Wixon, J. (2007) Gene therapy clinical trials worldwide to 2007: An update. Journal of Gene Medicine, 9, 833-842. doi:10.1002/jgm.1100

[2]   O’Reilly, M., Shipp, A., Rosenthal, E., Jambou, R., Shih, T., Montgomery, M., Gargiulo, L., Patterson, A. and Corrigan-Curay, J. (2012) NIH oversight of human gene transfer research involving retroviral, lentiviral, and adenoassociated virus vectors and the role of the NIH recombinant DNA advisory committee. Methods in Enzymology, 507, 313-335. doi:10.1016/B978-0-12-386509-0.00016-8

[3]   Giacca, M. and Zacchigna, S. (2012) Virus-mediated gene delivery for human gene therapy. Journal of Controlled Release, 161, 377-388. doi:10.1016/j.jconrel.2012.04.008

[4]   Raper, S.E., Chirmule, N., Lee, F.S., Wivel, N.A., Bagg, A., Gao, G.P., Wilson, J.M. and Batshaw, M.L. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular and Genetic Metabolism, 80, 148-158. doi:10.1016/j.ymgme.2003.08.016

[5]   Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.L., Bousso, P., Deist, F.L. and Fischer, A. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 288, 669-672. doi:10.1126/science.288.5466.669

[6]   Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.L., Fraser, C.C., Cavazzana-Calvo, M. and Fischer, A. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine, 348, 255-256. doi:10.1056/NEJM200301163480314

[7]   Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J.I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L.E., Wissler, M., Prinz, C., Rabbitts, T.H., Le Deist, F., Fischer, A. and Cavazzana-Calvo, M. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415-419. doi:10.1126/science.1088547

[8]   Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., Asnafi, V., MacIntyre, E., Dal Cortivo, L., Radford, I., Brousse, N., Sigaux, F., Moshous, D., Hauer, J., Borkhardt, A., Belohradsky, B.H., Wintergerst, U., Velez, M.C., Leiva, L., Sorensen, R., Wulffraat, N., Blanche, S., Bushman, F.D., Fischer, A. and Cavazzana-Calvo, M. (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. Journal of Clinical Investigation, 118, 3132-3142. doi:10.1172/JCI35700

[9]   Moiani, A. and Mavilio, F. (2012) Alternative splicing caused by lentiviral integration in the human genome. Methods in Enzymology, 507, 155-169. doi:10.1016/B978-0-12-386509-0.00008-9

[10]   Goncalves, M.A. (2005) Adeno-associated virus: From defective virus to effective vector. Virology Journal, 2, 43. doi:10.1186/1743-422X-2-43

[11]   Kotin, R.M., Menninger, J.C., Ward, D.C. and Berns, K.I. (1991) Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13qter. Genomics, 10, 831-834. doi:10.1016/0888-7543(91)90470-Y

[12]   Kotin, R.M., Siniscalco, M., Samulski, R.J., Zhu, X.D., Hunter, L., Laughlin, C.A., McLaughlin, S., Muzyczka, N., Rocchi, M. and Berns, K.I. (1990) Site-specific integration by adeno-associated virus. Proceedings of the National Academy of Sciences of the United States of America, 87, 2211-2215. doi:10.1073/pnas.87.6.2211

[13]   Samulski, R.J., Zhu, X., Xiao, X., Brook, J.D., Housman, D.E., Epstein, N. and Hunter, L.A. (1991) Targeted integration of adeno-associated virus (AAV) into human chromosome 19. The EMBO Journal, 10, 3941-3950.

[14]   Grieger, J.C. and Samulski, R.J. (2012) Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods in Enzymology, 507, 229-254. doi:10.1016/B978-0-12-386509-0.00012-0

[15]   Bainbridge, J.W., Smith, A.J., Barker, S.S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G.E., Stockman, A., Tyler, N., Petersen-Jones, S., Bhattacharya, S.S., Thrasher, A.J., Fitzke, F.W., Carter, B.J., Rubin, G.S., Moore, A.T. and Ali, R.R. (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. New England Journal of Medicine, 358, 2231-2239. doi:10.1056/NEJMoa0802268

[16]   Maguire, A.M., Simonelli, F., Pierce, E.A., Pugh Jr., E.N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K.A., Testa, F., Surace, E.M., Rossi, S., Lyubarsky, A., Arruda, V.R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell’Osso, L., Hertle, R., Ma, J.X., Redmond, T.M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K.S., Maguire, M.G., Wright, J.F., Volpe, N.J., McDonnell, J.W., Auricchio, A., High, K.A. and Bennett, J. (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis. New England Journal of Medicine, 358, 2240-2248. doi:10.1056/NEJMoa0802315

[17]   Riviere, C., Danos, O. and Douar, A.M. (2006) Longterm expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Therapy, 13, 1300-1308. doi:10.1038/sj.gt.3302766

[18]   Hartman, Z.C., Appledorn, D.M. and Amalfitano, A. (2008) Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Research, 132, 1-14. doi:10.1016/j.virusres.2007.10.005

[19]   Patel, D.H. and Misra, A. (2011) Gene delivery using viral vectors. In: Misra, A., Ed., Challenges in Delivery of Therapeutic Genomics and Proteomics, Elsevier, Amsterdam, 207-270. doi:10.1016/B978-0-12-384964-9.00005-0

[20]   Chénais, B., Caruso, A., Hiard, S. and Casse, N. (2012) The impact of transposable elements on eukaryotic genomes: From genome size increase to genetic adaptation to stressful environments. Gene, 509, 7-15. doi:10.1016/j.gene.2012.07.042

[21]   Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D., Harris, K., Heaford, A., Howland, J., Kann, L., Lehoczky, J., LeVine, R., McEwan, P., McKernan, K., Meldrim, J., Mesirov, J.P., Miranda, C., Morris, W., Naylor, J., Raymond, C., Rosetti, M., Santos, R., Sheridan, A., Sougnez, C., Stange-Thomann, N., Stojanovic, N., Subramanian, A., Wyman, D., Rogers, J., Sulston, J., Ainscough, R., Beck, S., Bentley, D., Burton, J., Clee, C., Carter, N., Coulson, A., Deadman, R., Deloukas, P., Dunham, A., Dunham, I., Durbin, R., French, L., Grafham, D., Gregory, S., Hubbard, T., Humphray, S., Hunt, A., Jones, M., Lloyd, C., McMurray, A., Matthews, L., Mercer, S., Milne, S., Mullikin, J.C., Mungall, A., Plumb, R., Ross, M., Shownkeen, R., Sims, S., Waterston, R.H., Wilson, R.K., Hillier, L.W., McPherson, J.D., Marra, M.A., Mardis, E.R., Fulton, L.A., Chinwalla, A.T., Pepin, K.H., Gish, W.R., Chissoe, S.L., Wendl, M.C., Delehaunty, K.D., Miner, T.L., Delehaunty, A., Kramer, J.B., Cook, L.L., Fulton, R.S., Johnson, D.L., Minx, P.J., Clifton, S.W., Hawkins, T., Branscomb, E., Predki, P., Richardson, P., Wenning, S., Slezak, T., Doggett, N., Cheng, J.F., Olsen, A., Lucas, S., Elkin, C., Uberbacher, E., Frazier, M., Gibbs, R.A., Muzny, D.M., Scherer, S.E., Bouck, J.B., Sodergren, E.J., Worley, K.C., Rives, C.M., Gorrell, J.H., Metzker, M.L., Naylor, S.L., Kucherlapati, R.S., Nelson, D.L., Weinstock, G.M., Sakaki, Y., Fujiyama, A., Hattori, M., Yada, T., Toyoda, A., Itoh, T., Kawagoe, C., Watanabe, H., Totoki, Y., Taylor, T., Weissenbach, J., Heilig, R., Saurin, W., Artiguenave, F., Brottier, P., Bruls, T., Pelletier, E., Robert, C., Wincker, P., Smith, D.R., Doucette-Stamm, L., Rubenfield, M., Weinstock, K., Lee, H.M., Dubois, J., Rosenthal, A., Platzer, M., Nyakatura, G., Taudien, S., Rump, A., Yang, H., Yu, J., Wang, J., Huang, G., Gu, J., Hood, L., Rowen, L., Madan, A., Qin, S., Davis, R.W., Federspiel, N.A., Abola, A.P., Proctor, M.J., Myers, R.M., Schmutz, J., Dickson, M., Grimwood, J., Cox, D.R., Olson, M.V., Kaul, R., Shimizu, N., Kawasaki, K., Minoshima, S., Evans, G.A., Athanasiou, M., Schultz, R., Roe, B.A., Chen, F., Pan, H., Ramser, J., Lehrach, H., Reinhardt, R., McCombie, W.R., de la Bastide, M., Dedhia, N., Blocker, H., Hornischer, K., Nordsiek, G., Agarwala, R., Aravind, L., Bailey, J.A., Bateman, A., Batzoglou, S., Birney, E., Bork, P., Brown, D.G., Burge, C.B., Cerutti, L., Chen, H.C., Church, D., Clamp, M., Copley, R.R., Doerks, T., Eddy, S.R., Eichler, E.E., Furey, T.S., Galagan, J., Gilbert, J.G., Harmon, C., Hayashizaki, Y., Haussler, D., Hermjakob, H., Hokamp, K., Jang, W., Johnson, L.S., Jones, T.A., Kasif, S., Kaspryzk, A., Kennedy, S., Kent, W.J., Kitts, P., Koonin, E.V., Korf, I., Kulp, D., Lancet, D., Lowe, T.M., McLysaght, A., Mikkelsen, T., Moran, J.V., Mulder, N., Pollara, V.J., Ponting, C.P., Schuler, G., Schultz, J., Slater, G., Smit, A.F., Stupka, E., Szustakowski, J., Thierry-Mieg, D., Thierry-Mieg, J., Wagner, L., Wallis, J., Wheeler, R., Williams, A., Wolf, Y.I., Wolfe, K.H., Yang, S.P., Yeh, R.F., Collins, F., Guyer, M.S., Peterson, J., Felsenfeld, A., Wetterstrand, K.A., Patrinos, A., Morgan, M.J., de Jong, P., Catanese, J.J., Osoegawa, K., Shizuya, H., Choi, S. and Chen, Y.J. (2001) Initial sequencing and analysis of the human genome. Nature, 409, 860-921. doi:10.1038/35057062

[22]   Delauriere, L., Chénais, B., Hardivillier, Y., Gauvry, L. and Casse, N. (2009) Mariner transposons as genetic tools in vertebrate cells. Genetica, 137, 9-17. doi:10.1007/s10709-009-9370-2

[23]   Ivics, Z., Li, M.A., Mates, L., Boeke, J.D., Nagy, A., Bradley, A. and Izsvak, Z., (2009) Transposon-mediated genome manipulation in vertebrates. Nature Methods, 6, 415-422. doi:10.1038/nmeth.1332

[24]   Ivics, Z. and Izsvak, Z. (2010) The expanding universe of transposon technologies for gene and cell engineering. Mobile DNA, 1, 25. doi:10.1186/1759-8753-1-25

[25]   Kawakami, K. (2007) Tol2: A versatile gene transfer vector in vertebrates. Genome Biology, 8, S1-S7. doi:10.1186/gb-2007-8-s1-s7

[26]   O’Brochta, D.A. and Handler, A.M. (2008) Perspectives on the state of insect transgenics. Advances in Experimental Medicine and Biology, 627, 1-18. doi:10.1007/978-0-387-78225-6_1

[27]   Thibault, S.T., Singer, M.A., Miyazaki, W.Y., Milash, B., Dompe, N.A., Singh, C.M., Buchholz, R., Demsky, M., Fawcett, R., Francis-Lang, H.L., Ryner, L., Cheung, L.M., Chong, A., Erickson, C., Fisher, W.W., Greer, K., Hartouni, S.R., Howie, E., Jakkula, L., Joo, D., Killpack, K., Laufer, A., Mazzotta, J., Smith, R.D., Stevens, L.M., Stuber, C., Tan, L.R., Ventura, R., Woo, A., Zakrajsek, I., Zhao, L., Chen, F., Swimmer, C., Kopczynski, C., Duyk, G., Winberg, M.L. and Margolis, J., (2004) A complementary transposon tool kit for Drosophila melanogaster using P and piggyBac. Nature Genetics, 36, 283-287. doi:10.1038/ng1314

[28]   Ding, S., Wu, X., Li, G., Han, M., Zhuang, Y. and Xu, T., (2005) Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell, 122, 473-483. doi:10.1016/j.cell.2005.07.013

[29]   Wilson, M.H., Coates, C.J. and George Jr., A.L. (2007) PiggyBac transposon-mediated gene transfer in human cells. Molecular Therapy, 15, 139-145. doi:10.1038/sj.mt.6300028

[30]   Wu, S.C., Meir, Y.J., Coates, C.J., Handler, A.M., Pelczar, P., Moisyadi, S. and Kaminski, J.M. (2006) PiggyBac is a flexible and highly active transposon as compared to sleeping beauty, Tol2, and Mos1 in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 103, 15008-15013. doi:10.1073/pnas.0606979103

[31]   Miller, W.J. and Capy, P. (2004) Mobile genetic elements as natural tools for genome evolution. Methods in Molecular Biology, 260, 1-20.

[32]   Schetelig, M.F., Gotschel, F., Viktorinova, I., Handler, A.M. and Wimmer, E.A. (2011) Recombination technologies for enhanced transgene stability in bioengineered insects. Genetica, 139, 71-78. doi:10.1007/s10709-010-9494-4

[33]   Keravala, A., Liu, D., Lechman, E.R., Wolfe, D., Nash, J.A., Lampe, D.J. and Robbins, P.D. (2006) Hyperactive Himar1 transposase mediates transposition in cell culture and enhances gene expression in vivo. Human Gene Therapy, 17, 1006-1018. doi:10.1089/hum.2006.17.1006

[34]   Hackett Jr., P.B., Aronovich, E.L., Hunter, D., Urness, M., Bell, J.B., Kass, S.J., Cooper, L.J. and McIvor, S. (2011) Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Current Gene Therapy, 11, 341-349. doi:10.2174/156652311797415827

[35]   Hackett, P.B., Largaespada, D.A. and Cooper, L.J. (2010) A transposon and transposase system for human application. Molecular Therapy, 18, 674-683. doi:10.1038/mt.2010.2

[36]   Ivics, Z. and Izsvak, Z. (2011) Nonviral gene delivery with the sleeping beauty transposon system. Human Gene Therapy, 22, 1043-1051. doi:10.1089/hum.2011.143

[37]   Izsvak, Z., Hackett, P.B., Cooper, L.J. and Ivics, Z. (2010) Translating sleeping beauty transposition into cellular therapies: Victories and challenges. BioEssays, 32, 756-767. doi:10.1002/bies.201000027

[38]   Balciunas, D., Wangensteen, K.J., Wilber, A., Bell, J., Geurts, A., Sivasubbu, S., Wang, X., Hackett, P.B., Largaespada, D.A., McIvor, R.S. and Ekker, S.C. (2006) Harnessing a high cargo-capacity transposon for genetic applications in vertebrates. PLoS Genetics, 2, e169. doi:10.1371/journal.pgen.0020169

[39]   Suster, M.L., Sumiyama, K. and Kawakami, K. (2009) Transposon-mediated BAC transgenesis in zebrafish and mice. BMC Genomics, 10, 477. doi:10.1186/1471-2164-10-477

[40]   Izsvak, Z., Ivics, Z. and Plasterk, R.H. (2000) Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. Journal of Molecular Biology, 302, 93-102. doi:10.1006/jmbi.2000.4047

[41]   Mates, L., Chuah, M.K., Belay, E., Jerchow, B., Manoj, N., Acosta-Sanchez, A., Grzela, D.P., Schmitt, A., Becker, K., Matrai, J., Ma, L., Samara-Kuko, E., Gysemans, C., Pryputniewicz, D., Miskey, C., Fletcher, B., VandenDriessche, T., Ivics, Z. and Izsvak, Z. (2009) Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nature Genetics, 41, 753-761. doi:10.1038/ng.343

[42]   Geurts, A.M., Yang, Y., Clark, K.J., Liu, G., Cui, Z., Dupuy, A.J., Bell, J.B., Largaespada, D.A. and Hackett, P.B. (2003) Gene transfer into genomes of human cells by the sleeping beauty transposon system. Molecular Therapy, 8, 108-117. doi:10.1016/S1525-0016(03)00099-6

[43]   Cadinanos, J. and Bradley, A. (2007) Generation of an inducible and optimized piggyBac transposon system. Nucleic Acids Research, 35, e87. doi:10.1093/nar/gkm446

[44]   Yusa, K., Zhou, L., Li, M.A., Bradley, A. and Craig, N.L. (2011) A hyperactive piggyBac transposase for mammalian applications. Proceedings of the National Academy of Sciences of the United States of America, 108, 1531-1536. doi:10.1073/pnas.1008322108

[45]   Grabundzija, I., Irgang, M., Mates, L., Belay, E., Matrai, J., Gogol-Doring, A., Kawakami, K., Chen, W., Ruiz, P., Chuah, M.K., VandenDriessche, T., Izsvak, Z. and Ivics, Z. (2010) Comparative analysis of transposable element vector systems in human cells. Molecular Therapy, 18, 1200-1209. doi:10.1038/mt.2010.47

[46]   Garrison, B.S., Yant, S.R., Mikkelsen, J.G. and Kay, M.A. (2007) Postintegrative gene silencing within the Sleeping Beauty transposition system. Molecular and Cellular Biology, 27, 8824-8833. doi:10.1128/MCB.00498-07

[47]   Meir, Y.J. and Wu, S.C. (2011) Transposon-based vector systems for gene therapy clinical trials: Challenges and considerations. Chang Gung Medicine Journal, 34, 565-579.

[48]   Meir, Y.J., Weirauch, M.T., Yang, H.S., Chung, P.C., Yu, R.K. and Wu, S.C. (2011) Genome-wide target profiling of piggyBac and Tol2 in HEK 293: Pros and cons for gene discovery and gene therapy. BMC Biotechnology, 11, 28. doi:10.1186/1472-6750-11-28

[49]   Shi, X., Harrison, R.L., Hollister, J.R., Mohammed, A., Fraser Jr., M.J. and Jarvis, D.L. (2007) Construction and characterization of new piggyBac vectors for constitutive or inducible expression of heterologous gene pairs and the identification of a previously unrecognized activator sequence in piggyBac. BMC Biotechnology, 7, 5. doi:10.1186/1472-6750-7-5

[50]   Huang, X., Guo, H., Tammana, S., Jung, Y.C., Mellgren, E., Bassi, P., Cao, Q., Tu, Z.J., Kim, Y.C., Ekker, S.C., Wu, X., Wang, S.M. and Zhou, X. (2010) Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. Molecular Therapy, 18, 1803-1813. doi:10.1038/mt.2010.141

[51]   Mitchell, R.S., Beitzel, B.F., Schroder, A.R., Shinn, P., Chen, H., Berry, C.C., Ecker, J.R. and Bushman, F.D. (2004) Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biology, 2, e234. doi:10.1371/journal.pbio.0020234

[52]   Nakai, H., Montini, E., Fuess, S., Storm, T.A., Grompe, M. and Kay, M.A. (2003) AAV serotype 2 vectors preferentially integrate into active genes in mice. Nature Genetics, 34, 297-302. doi:10.1038/ng1179

[53]   Nienhuis, A.W., Dunbar, C.E. and Sorrentino, B.P. (2006) Genotoxicity of retroviral integration in hematopoietic cells. Molecular Therapy, 13, 1031-1049. doi:10.1016/j.ymthe.2006.03.001

[54]   Wu, X., Li, Y., Crise, B. and Burgess, S.M. (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science, 300, 1749-1751. doi:10.1126/science.1083413

[55]   Galvan, D.L., Nakazawa, Y., Kaja, A., Kettlun, C., Cooper, L.J., Rooney, C.M. and Wilson, M.H. (2009) Genome-wide mapping of PiggyBac transposon integrations in primary human T cells. Journal of Immunotherapy, 32, 837-844. doi:10.1097/CJI.0b013e3181b2914c

[56]   Yant, S.R., Wu, X., Huang, Y., Garrison, B., Burgess, S.M. and Kay, M.A. (2005) High-resolution genomewide mapping of transposon integration in mammals. Molecular and Cellular Biology, 25, 2085-2094. doi:10.1128/MCB.25.6.2085-2094.2005

[57]   Yant, S.R., Meuse, L., Chiu, W., Ivics, Z., Izsvak, Z. and Kay, M.A. (2000) Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nature Genetics, 25, 35-41. doi:10.1038/75568

[58]   Montini, E., Held, P.K., Noll, M., Morcinek, N., AlDhalimy, M., Finegold, M., Yant, S.R., Kay, M.A. and Grompe, M. (2002) In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Molecular Therapy, 6, 759-769. doi:10.1006/mthe.2002.0812

[59]   Ortiz-Urda, S., Lin, Q., Yant, S.R., Keene, D., Kay, M.A. and Khavari, P.A. (2003) Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Therapy, 10, 1099-1104. doi:10.1038/sj.gt.3301978

[60]   Liu, L., Mah, C. and Fletcher, B.S. (2006) Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon. Molecular Therapy, 13, 1006-1015. doi:10.1016/j.ymthe.2005.11.021

[61]   Ohlfest, J.R., Frandsen, J.L., Fritz, S., Lobitz, P.D., Perkinson, S.G., Clark, K.J., Nelsestuen, G., Key, N.S., McIvor, R.S., Hackett, P.B. and Largaespada, D.A. (2005) Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood, 105, 2691-2698. doi:10.1182/blood-2004-09-3496

[62]   Kren, B.T., Unger, G.M., Sjeklocha, L., Trossen, A.A., Korman, V., Diethelm-Okita, B.M., Reding, M.T. and Steer, C.J. (2009) Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. Journal of Clinical Investigation, 119, 2086-2099.

[63]   Liu, H., Liu, L., Fletcher, B.S. and Visner, G.A. (2006) Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. FASEB Journal, 20, 2384-2386. doi:10.1096/fj.06-6228fje

[64]   Aronovich, E.L., Bell, J.B., Khan, S.A., Belur, L.R., Gunther, R., Koniar, B., Schachern, P.A., Parker, J.B., Carlson, C.S., Whitley, C.B., McIvor, R.S., Gupta, P. and Hackett, P.B. (2009) Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Molecular Therapy, 17, 1136-1144. doi:10.1038/mt.2009.87

[65]   Aronovich, E.L., Bell, J.B., Belur, L.R., Gunther, R., Koniar, B., Erickson, D.C., Schachern, P.A., Matise, I., McIvor, R.S., Whitley, C.B. and Hackett, P.B. (2007) Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: Implications for non-viral gene therapy of mucopolysaccharidoses. Journal of Gene Medicine, 9, 403-415. doi:10.1002/jgm.1028

[66]   Wang, X., Sarkar, D.P., Mani, P., Steer, C.J., Chen, Y., Guha, C., Chandrasekhar, V., Chaudhuri, A., Roy-Chowdhury, N., Kren, B.T. and Roy-Chowdhury, J. (2009) Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon. Hepatology, 50, 815-824. doi:10.1002/hep.23060

[67]   Hyland, K.A., Olson, E.R., Clark, K.J., Aronovich, E.L., Hackett, P.B., Blazar, B.R., Tolar, J. and Scott McIvor, R. (2011) Sleeping Beauty-mediated correction of Fanconi anemia type C. Journal of Gene Medicine, 13, 462-469. doi:10.1002/jgm.1589

[68]   Johnen, S., Izsvak, Z., Stocker, M., Harmening, N., Salz, A.K., Walter, P. and Thumann, G. (2012) Sleeping Beauty transposon-mediated transfection of retinal and iris pigment epithelial cells. Investigative Ophthalmology and Visual Science, 53, 4787-4796. doi:10.1167/iovs.12-9951

[69]   Ohlfest, J.R., Demorest, Z.L., Motooka, Y., Vengco, I., Oh, S., Chen, E., Scappaticci, F.A., Saplis, R.J., Ekker, S.C., Low, W.C., Freese, A.B. and Largaespada, D.A. (2005) Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Molecular Therapy, 12, 778-788. doi:10.1016/j.ymthe.2005.07.689

[70]   Kang, Y., Zhang, X., Jiang, W., Wu, C., Chen, C., Zheng, Y., Gu, J. and Xu, C. (2009) Tumor-directed gene therapy in mice using a composite nonviral gene delivery system consisting of the piggyBac transposon and polyethyleneimine. BMC Cancer, 9, 126. doi:10.1186/1471-2407-9-126

[71]   Nakazawa, Y., Huye, L.E., Salsman, V.S., Leen, A.M., Ahmed, N., Rollins, L., Dotti, G., Gottschalk, S.M., Wilson, M.H. and Rooney, C.M. (2011) PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic Tcells expressing HER2-specific chimeric antigen receptor. Molecular Therapy, 19, 2133-2143. doi:10.1038/mt.2011.131

[72]   Kang, Y., Zhang, X.Y., Jiang, W., Wu, C.Q., Chen, C.M., Gu, J.R., Zheng, Y.F. and Xu, C.J. (2009) The piggyBac transposon is an integrating non-viral gene transfer vector that enhances the efficiency of GDEPT. Cell Biology International, 33, 509-515. doi:10.1016/j.cellbi.2009.01.017

[73]   Hollis, R.P., Nightingale, S.J., Wang, X., Pepper, K.A., Yu, X.J., Barsky, L., Crooks, G.M. and Kohn, D.B. (2006) Stable gene transfer to human CD34+ hematopoietic cells using the Sleeping Beauty transposon. Experimental Hematology, 34, 1333-1343. doi:10.1016/j.exphem.2006.05.023

[74]   Izsvak, Z., Chuah, M.K., Vandendriessche, T. and Ivics, Z. (2009) Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods, 49, 287-297. doi:10.1016/j.ymeth.2009.07.001

[75]   Sumiyoshi, T., Holt, N.G., Hollis, R.P., Ge, S., Cannon, P.M., Crooks, G.M. and Kohn, D.B. (2009) Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Human Gene Therapy, 20, 1607-1626. doi:10.1089/hum.2009.109

[76]   Xue, X., Huang, X., Nodland, S.E., Mates, L., Ma, L., Izsvak, Z., Ivics, Z., LeBien, T.W., McIvor, R.S., Wagner, J.E. and Zhou, X. (2009) Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood, 114, 1319-1330. doi:10.1182/blood-2009-03-210005

[77]   Huang, X., Guo, H., Kang, J., Choi, S., Zhou, T.C., Tammana, S., Lees, C.J., Li, Z.Z., Milone, M., Levine, B.L., Tolar, J., June, C.H., Scott McIvor, R., Wagner, J.E., Blazar, B.R. and Zhou, X. (2008) Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Molecular Therapy, 16, 580-589. doi:10.1038/sj.mt.6300404

[78]   Huang, X., Wilber, A., McIvor, R.S. and Zhou, X. (2009) DNA transposons for modification of human primary T lymphocytes. Methods in Molecular Biology, 506, 115-126. doi:10.1007/978-1-59745-409-4_9

[79]   Manuri, P.V., Wilson, M.H., Maiti, S.N., Mi, T., Singh, H., Olivares, S., Dawson, M.J., Huls, H., Lee, D.A., Rao, P.H., Kaminski, J.M., Nakazawa, Y., Gottschalk, S., Kebriaei, P., Shpall, E.J., Champlin, R.E. and Cooper, L.J. (2010) Piggybac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Human Gene Therapy, 21, 427-437. doi:10.1089/hum.2009.114

[80]   Nakazawa, Y., Huye, L.E., Dotti, G., Foster, A.E., Vera, J.F., Manuri, P.R., June, C.H., Rooney, C.M. and Wilson, M.H. (2009) Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. Journal of Immunotherapy, 32, 826-836. doi:10.1097/CJI.0b013e3181ad762b

[81]   Singh, H., Manuri, P.R., Olivares, S., Dara, N., Dawson, M.J., Huls, H., Hackett, P.B., Kohn, D.B., Shpall, E.J., Champlin, R.E. and Cooper, L.J. (2008) Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Research, 68, 2961-2971. doi:10.1158/0008-5472.CAN-07-5600

[82]   Orban, T.I., Apati, A., Nemeth, A., Varga, N., Krizsik, V., Schamberger, A., Szebenyi, K., Erdei, Z., Varady, G., Karaszi, E., Homolya, L., Nemet, K., Gocza, E., Miskey, C., Mates, L., Ivics, Z., Izsvak, Z. and Sarkadi, B. (2009) Applying a “double-feature” promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery. Stem Cells, 27, 1077-1087. doi:10.1002/stem.45

[83]   Wilber, A., Linehan, J.L., Tian, X., Woll, P.S., Morris, J.K., Belur, L.R., McIvor, R.S. and Kaufman, D.S. (2007) Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells, 25, 2919-2927. doi:10.1634/stemcells.2007-0026

[84]   Williams, D.A. (2008) Sleeping beauty vector system moves toward human trials in the United States. Molecular Therapy, 16, 1515-1516. doi:10.1038/mt.2008.169

[85]   Jena, B., Dotti, G. and Cooper, L.J. (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood, 116, 1035-1044. doi:10.1182/blood-2010-01-043737

[86]   Kebriaei, P., Huls, H., Jena, B., Munsell, M., Jackson, R., Lee, D.A., Hackett, P.B., Rondon, G., Shpall, E., Champlin, R.E. and Cooper, L.J. (2012) Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Human Gene Therapy, 23, 444-450. doi:10.1089/hum.2011.167

[87]   Torikai, H., Reik, A., Liu, P.Q., Zhou, Y., Zhang, L., Maiti, S., Huls, H., Miller, J.C., Kebriaei, P., Rabinovitch, B., Lee, D.A., Champlin, R.E., Bonini, C., Naldini, L., Rebar, E.J., Gregory, P.D., Holmes, M.C. and Cooper, L.J. (2012) A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood, 119, 5697-5705. doi:10.1182/blood-2012-01-405365

[88]   Delauriere, L., Chénais, B., Pradier, E., Hardivillier, Y., Renault, S. and Casse, N. (2009) DNA binding specificity and cleavage activity of Pacmmar transposase. Biochemistry, 48, 7279-7286. doi:10-.1021/bi900609v

[89]   de Silva, S., Lotta Jr., L.T., Burris, C.A. and Bowers, W.J. (2010) Virion-associated cofactor high-mobility group DNA-binding protein-1 facilitates transposition from the herpes simplex virus/Sleeping Beauty amplicon vector platform. Human Gene Therapy, 21, 1615-1622. doi:10.1089/hum.2010.022

[90]   Moldt, B., Miskey, C., Staunstrup, N.H., Gogol-Doring, A., Bak, R.O., Sharma, N., Mates, L., Izsvak, Z., Chen, W., Ivics, Z. and Mikkelsen, J.G. (2011) Comparative genomic integration profiling of Sleeping Beauty transposons mobilized with high efficacy from integrase-defective lentiviral vectors in primary human cells. Molecular Therapy, 19, 1499-1510. doi:10.1038/mt.2011.47

[91]   Vink, C.A., Gaspar, H.B., Gabriel, R., Schmidt, M., McIvor, R.S., Thrasher, A.J. and Qasim, W. (2009) Sleeping beauty transposition from nonintegrating lentivirus. Molecular Therapy, 17, 1197-1204. doi:10.1038/mt.2009.94

[92]   Ehrhardt, A., Yant, S.R., Giering, J.C., Xu, H., Engler, J.A. and Kay, M.A. (2007) Somatic integration from an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene expression levels in vivo. Molecular Therapy, 15, 146-156. doi:10.1038/sj.mt.6300011

[93]   Yant, S.R., Ehrhardt, A., Mikkelsen, J.G., Meuse, L., Pham, T. and Kay, M.A. (2002) Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nature Biotechnology, 20, 999-1005. doi:10.1038/nbt738

[94]   Yant, S.R., Huang, Y., Akache, B. and Kay, M.A. (2007) Site-directed transposon integration in human cells. Nucleic Acids Research, 35, e50. doi:10.1093/nar/gkm089

[95]   Hausl, M., Zhang, W., Voigtlander, R., Muther, N., Rauschhuber, C. and Ehrhardt, A. (2011) Development of adenovirus hybrid vectors for Sleeping Beauty transposetion in large mammals. Current Gene Therapy, 11, 363-374. doi:10.2174/156652311797415890

[96]   Luo, W.Y., Shih, Y.S., Hung, C.L., Lo, K.W., Chiang, C.S., Lo, W.H., Huang, S.F., Wang, S.C., Yu, C.F., Chien, C.H. and Hu, Y.C. (2012) Development of the hybrid Sleeping Beauty: Baculovirus vector for sustained gene expression and cancer therapy. Gene Therapy, 19, 844-851. doi:10.1038/gt.2011.129

[97]   Liu, L., Liu, H., Visner, G. and Fletcher, B.S. (2006) Sleeping Beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats. FASEB Journal, 20, 2594-2596. doi:10.1096/fj.06-6254fje

[98]   Singh, H., Figliola, M.J., Dawson, M.J., Huls, H., Olivares, S., Switzer, K., Mi, T., Maiti, S., Kebriaei, P., Lee, D.A., Champlin, R.E. and Cooper, L.J. (2011) Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignnancies. Cancer Research, 71, 3516-3527. doi:10.1158/0008-5472.CAN-10-3843

[99]   Staunstrup, N.H., Madsen, J., Primo, M.N., Li, J., Liu, Y., Kragh, P.M., Li, R., Schmidt, M., Purup, S., DagnaesHansen, F., Svensson, L., Petersen, T.K., Callesen, H., Bolund, L. and Mikkelsen, J.G. (2012) Development of transgenic cloned pig models of skin inflammation by DNA transposon-directed ectopic expression of human beta1 and alpha2 integrin. PLoS One, 7, e36658. doi:10.1371/journal.pone.0036658

[100]   Huang, G., Yu, L., Cooper, L.J., Hollomon, M., Huls, H. and Kleinerman, E.S. (2012) Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Research, 72, 271-281. doi:10.1158/0008-5472.CAN-11-2778

[101]   Xiao, J., Meng, X.M., Huang, X.R., Chung, A.C., Feng, Y.L., Hui, D.S., Yu, C.M., Sung, J.J. and Lan, H.Y. (2012) MiR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Molecular Therapy, 20, 1251-1260. doi:10.1038/mt.2012.36

 
 
Top